$1.68 Billion is the total value of Sofinnova Investments, Inc.'s 69 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 63.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABBV | Sell | Abbvie Inc | $31,459,000 | +5.2% | 293,596 | -14.0% | 1.87% | -15.5% |
| PTCT | Sell | PTC Therapeutics Inc | $19,315,000 | +2.0% | 316,478 | -21.9% | 1.15% | -18.1% |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $14,429,000 | -26.7% | 164,545 | -36.4% | 0.86% | -41.1% |
| INSM | Sell | Insmed Inc | $10,309,000 | -47.9% | 309,662 | -49.7% | 0.61% | -58.1% |
| LLY | Sell | Eli Lilly and Co | $6,232,000 | -70.4% | 36,909 | -74.1% | 0.37% | -76.3% |
| XLRN | Sell | Acceleron Pharma Inc | $4,694,000 | -29.9% | 36,688 | -38.4% | 0.28% | -43.9% |
| KURA | Sell | Kura Oncology Inc | $3,941,000 | -42.9% | 120,677 | -46.4% | 0.24% | -54.1% |
| TGTX | Sell | TG Therapeutics Inc | $3,406,000 | -49.2% | 65,474 | -73.9% | 0.20% | -59.2% |
| IMTX | Sell | Immatics NV | $3,016,000 | -12.7% | 279,532 | -14.1% | 0.18% | -29.7% |
| FATE | Sell | Fate Therapeutics Inc | $1,227,000 | -25.8% | 13,497 | -67.4% | 0.07% | -40.7% |
| KDMN | Sell | Kadmon Holdings Inc | $950,000 | -61.5% | 228,893 | -63.7% | 0.06% | -68.9% |
| LQDA | Sell | Liquidia Corp | $436,000 | -87.0% | 147,744 | -78.3% | 0.03% | -89.5% |
| Exit | Kadmon Holdings Incwarrant | $0 | – | -240,091 | -100.0% | -0.01% | – | |
| SVRA | Exit | Savara Inc | $0 | – | -375,591 | -100.0% | -0.03% | – |
| ETTX | Exit | Entasis Therapeutics Holdings Inc. | $0 | – | -1,012,408 | -100.0% | -0.15% | – |
| CGEN | Exit | Compugen Ltd | $0 | – | -146,592 | -100.0% | -0.18% | – |
| FIXX | Exit | Homology Medicines Inc | $0 | – | -238,015 | -100.0% | -0.19% | – |
| Exit | Moderna Inccall | $0 | – | -50,000 | -100.0% | -0.26% | – | |
| AGTC | Exit | Applied Genetic Technologies Corp | $0 | – | -825,071 | -100.0% | -0.30% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals, Ltd | $0 | – | -276,628 | -100.0% | -0.31% | – |
| CHMA | Exit | Chiasma | $0 | – | -1,047,354 | -100.0% | -0.33% | – |
| Exit | Novocure Ltdcall | $0 | – | -50,000 | -100.0% | -0.41% | – | |
| Exit | Reata Pharmaceuticals Incput | $0 | – | -60,000 | -100.0% | -0.43% | – | |
| OVID | Exit | Ovid Therapeutics Inc | $0 | – | -1,097,621 | -100.0% | -0.47% | – |
| MYOK | Exit | MyoKardia Inc | $0 | – | -48,998 | -100.0% | -0.50% | – |
| SUPN | Exit | Supernus Pharmaceuticals Inc | $0 | – | -330,295 | -100.0% | -0.51% | – |
| PTGX | Exit | Protagonist Therapeutics Inc | $0 | – | -357,769 | -100.0% | -0.52% | – |
| Exit | Cytokinetics Incput | $0 | – | -325,000 | -100.0% | -0.52% | – | |
| ZYME | Exit | Zymeworks Inc | $0 | – | -151,902 | -100.0% | -0.52% | – |
| Exit | Marinus Pharmaceuticals Inccall | $0 | – | -175,000 | -100.0% | -0.67% | – | |
| MRK | Exit | Merck & Co Inc | $0 | – | -190,559 | -100.0% | -1.17% | – |
| NXTC | Exit | Nextcure, Inc | $0 | – | -2,671,856 | -100.0% | -1.74% | – |
| Exit | Amgen Inccall | $0 | – | -59,500 | -100.0% | -3.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.